ESPR PDUFA decision: a positive outcome, -9.6%

On February 21, 2020, Esperion Therapeutics, Inc. reached its PDUFA decision. The result was a positive outcome, and the stock moved -9.6% in the window around the event. It had already run +18.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.